Skip to main content
graph.swiss
Sandoz Group AG

Sandoz Group AG

65.74 CHF+2.00 (+3.14%)
XSWX:SDZMarket Closed
ListedCHF28.4BHealthcareDrug Manufacturers - Specialty & Generic22,356 employees

Company Profile

Legal NameSandoz Group AG
CEOMr. Ahmed Khaled El-Hoshy
HeadquartersCentralbahnstrasse 4
Phone41 61 324 11 11
Employees (FTE)22,356
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic

Business Description

Sandoz Group AG is a Swiss company specializing in generic pharmaceuticals and biosimilars. It serves as the global leader in providing affordable generic and biosimilar medicines, with a purpose centered on pioneering access to treatments for patients worldwide. The company develops, manufactures, and commercializes a broad portfolio of off-patent medicines, including complex generics and high-value biosimilars that offer cost-effective alternatives to biologic therapies. Sandoz Group AG operates in key therapeutic areas such as oncology, immunology, endocrinology, and cardiovascular health, addressing critical needs in both developed and emerging markets. Its B2B business unit supplies active pharmaceutical ingredients, out-licenses finished dosage forms, and provides contract manufacturing services. Headquartered in Basel, Switzerland, with major operations in Holzkirchen, Germany; Prague, Czechia; Barcelona, Spain; and Kufstein, Austria, Sandoz Group AG plays a vital role in the healthcare sector by enhancing medicine affordability and availability through its extensive global footprint.

Profitability & Growth

Profitability

Profit Margin+8.19%
Operating Margin+14.31%
Return on Equity (TTM)+10.42%
Return on Assets (TTM)+4.31%

Recent Year-End

Revenue9.03B
Revenue / Share25.83
Gross Profit4.29B
EBITDA1.98B
Diluted EPS1.69
Revenue Growth YoY+10.70%

Balance Sheet Snapshot

Total Cash (MRQ)

1.41B

Total Debt (MRQ)

4.61B

Current Ratio (MRQ)

1.18

Book Value / Share

17.56

Stock Statistics

Shares Outstanding432.7M
Float Shares414.3M
Avg Volume (10d)635.1K
Avg Volume (90d)666.3K
% Held by Insiders+4.18%
% Held by Institutions+50.52%

Valuation

Market Cap28.45B
Enterprise Value26.03B
Trailing P/E38.35
Forward P/E17.23
PEG Ratio17.23
Price / Sales (TTM)2.51
Price / Book (MRQ)3.69
EV / Revenue2.88
EV / EBITDA17.00

Price Summary

52-Week Low43.86
52-Week High74.72
50-Day MA67.41
200-Day MA61.44
Beta0.50

Dividends

Forward Div Rate3.20
Forward Div Yield+4.91%
Trailing Div Rate0.80
Payout Ratio+34.86%
Dividend Date2025-04-23
Ex-Dividend Date2026-04-13